Jarvik 2000 (artificial heart)

2019: The first-ever cardiopump with wireless charging was implanted to the patient in Kazakhstan

At the beginning of February, 2019 the companies Jarvik Heart also Leviticus Cardio provided the first-ever cardiopump with wireless charging. Developers reported that the first patient to whom they installed the wireless left ventricular device of auxiliary blood circulation was operated in December, 2018 in the National research center of a heart surgery in Astana (Kazakhstan). Transaction took place successfully, and the patient was discharged from hospital.

Completely implanted wireless device of auxiliary blood circulation is the cardiopump Jarvik 2000 using the components developed by Leviticus Cardio company. The device, according to representatives the company, allows patients to move fully, without feeling short wind, till eight o'clock in day. The device is also equipped with standby system which will allow to pass to a traditional wire power supply in case of failure of a wireless system. Representatives of the companies say that though the backup copy was checked during the procedure of implantation, after need for it did not arise.

The first patient to whom installed the wireless left ventricular device of auxiliary blood circulation was operated in December, 2018 in the National research center of a heart surgery in Astana

Annually devices of auxiliary blood circulation are implanted to thousands of patients with heavy heart failure. Traditional cardiopumps require regular connection to the power source. The cord of a power supply is displaid through a belly wall of the patient and connected either to the socket, or to batteries.

It not only seriously reduces quality of life of patients, but in more than 20% of cases causes infections which can lead to hospitalization and serious complications. Besides, patients when using such technology should carry with themselves back-up batteries. The wireless device is deprived of these shortcomings that increases quality of life of patients and provides more favorable forecast.^[1]

Notes